Unicycive Therapeutics (UNCY) Competitors $4.68 +0.06 (+1.30%) As of 01:13 PM Eastern This is a fair market value price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsHeadlinesOwnershipSEC FilingsShort InterestTrendsBuy This Stock UNCY vs. ESPR, BTMD, NBTX, PRQR, SLRN, TVGN, MNPR, SXTC, SLS, and EDITShould you be buying Unicycive Therapeutics stock or one of its competitors? The main competitors of Unicycive Therapeutics include Esperion Therapeutics (ESPR), biote (BTMD), Nanobiotix (NBTX), ProQR Therapeutics (PRQR), Acelyrin (SLRN), Semper Paratus Acquisition (TVGN), Monopar Therapeutics (MNPR), China SXT Pharmaceuticals (SXTC), SELLAS Life Sciences Group (SLS), and Editas Medicine (EDIT). These companies are all part of the "pharmaceutical products" industry. Unicycive Therapeutics vs. Its Competitors Esperion Therapeutics biote Nanobiotix ProQR Therapeutics Acelyrin Semper Paratus Acquisition Monopar Therapeutics China SXT Pharmaceuticals SELLAS Life Sciences Group Editas Medicine Unicycive Therapeutics (NASDAQ:UNCY) and Esperion Therapeutics (NASDAQ:ESPR) are both small-cap medical companies, but which is the superior investment? We will compare the two companies based on the strength of their valuation, profitability, dividends, analyst recommendations, earnings, institutional ownership, media sentiment and risk. Which has better valuation & earnings, UNCY or ESPR? Unicycive Therapeutics has higher earnings, but lower revenue than Esperion Therapeutics. Esperion Therapeutics is trading at a lower price-to-earnings ratio than Unicycive Therapeutics, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioUnicycive Therapeutics$680K86.99-$36.73M-$5.10-0.92Esperion Therapeutics$332.31M0.67-$51.74M-$0.80-1.41 Do analysts recommend UNCY or ESPR? Unicycive Therapeutics presently has a consensus target price of $60.00, suggesting a potential upside of 1,182.05%. Esperion Therapeutics has a consensus target price of $7.00, suggesting a potential upside of 522.22%. Given Unicycive Therapeutics' stronger consensus rating and higher probable upside, equities analysts plainly believe Unicycive Therapeutics is more favorable than Esperion Therapeutics.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Unicycive Therapeutics 0 Sell rating(s) 0 Hold rating(s) 2 Buy rating(s) 1 Strong Buy rating(s) 3.33Esperion Therapeutics 0 Sell rating(s) 1 Hold rating(s) 4 Buy rating(s) 0 Strong Buy rating(s) 2.80 Does the media refer more to UNCY or ESPR? In the previous week, Esperion Therapeutics had 8 more articles in the media than Unicycive Therapeutics. MarketBeat recorded 11 mentions for Esperion Therapeutics and 3 mentions for Unicycive Therapeutics. Unicycive Therapeutics' average media sentiment score of 0.54 beat Esperion Therapeutics' score of 0.46 indicating that Unicycive Therapeutics is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Unicycive Therapeutics 0 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Esperion Therapeutics 2 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Neutral Which has more risk and volatility, UNCY or ESPR? Unicycive Therapeutics has a beta of 1.89, meaning that its share price is 89% more volatile than the S&P 500. Comparatively, Esperion Therapeutics has a beta of 0.7, meaning that its share price is 30% less volatile than the S&P 500. Do insiders & institutionals hold more shares of UNCY or ESPR? 40.4% of Unicycive Therapeutics shares are owned by institutional investors. Comparatively, 47.4% of Esperion Therapeutics shares are owned by institutional investors. 10.7% of Unicycive Therapeutics shares are owned by insiders. Comparatively, 1.7% of Esperion Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company will outperform the market over the long term. Is UNCY or ESPR more profitable? Unicycive Therapeutics has a net margin of 0.00% compared to Esperion Therapeutics' net margin of -59.03%. Esperion Therapeutics' return on equity of -0.91% beat Unicycive Therapeutics' return on equity.Company Net Margins Return on Equity Return on Assets Unicycive TherapeuticsN/A -277.30% -61.53% Esperion Therapeutics -59.03%-0.91%-29.47% SummaryUnicycive Therapeutics beats Esperion Therapeutics on 10 of the 17 factors compared between the two stocks. Get Unicycive Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for UNCY and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding UNCY and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart UNCY vs. The Competition Export to ExcelMetricUnicycive TherapeuticsMED IndustryMedical SectorNASDAQ ExchangeMarket Cap$59.16M$2.44B$5.56B$9.30BDividend YieldN/A1.79%4.23%4.03%P/E Ratio-0.929.1628.6119.64Price / Sales86.99735.94437.49188.30Price / CashN/A164.3436.0257.93Price / Book6.504.688.185.63Net Income-$36.73M$30.99M$3.23B$257.73M7 Day Performance-13.01%0.57%-0.25%0.07%1 Month Performance-37.96%7.91%5.40%8.32%1 Year Performance-0.85%-5.94%26.35%13.78% Unicycive Therapeutics Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)UNCYUnicycive Therapeutics2.9811 of 5 stars$4.68+1.3%$60.00+1,182.1%-7.4%$59.16M$680K-0.929ESPREsperion Therapeutics3.9253 of 5 stars$1.11-5.1%$7.00+530.6%-54.8%$231.89M$332.31M0.00200Analyst RevisionBTMDbiote3.236 of 5 stars$3.99-5.5%$8.00+100.5%-52.0%$230.88M$197.19M6.49194NBTXNanobiotix2.3162 of 5 stars$4.75-2.5%$8.00+68.6%-3.4%$229.54M$39.18M0.00100PRQRProQR Therapeutics2.3716 of 5 stars$2.14-1.8%$8.00+273.8%+34.9%$229.36M$20.46M0.00180SLRNAcelyrinN/A$2.27flat$9.60+322.9%N/A$229.17MN/A-0.92135TVGNSemper Paratus Acquisition3.9508 of 5 stars$1.20-3.2%$10.00+733.3%+69.0%$228.03MN/A0.003Gap DownMNPRMonopar Therapeutics2.1681 of 5 stars$37.20+2.6%$60.00+61.3%+1,020.0%$221.68MN/A0.0010SXTCChina SXT Pharmaceuticals0.9266 of 5 stars$1.69-10.1%N/A-82.3%$218.13M$1.93M0.0090SLSSELLAS Life Sciences Group0.354 of 5 stars$2.17flatN/A+74.3%$216.52M$1M0.0010News CoverageHigh Trading VolumeEDITEditas Medicine4.2238 of 5 stars$2.54-1.2%$4.70+85.0%-51.0%$215.14M$32.31M0.00230 Related Companies and Tools Related Companies Esperion Therapeutics Alternatives biote Alternatives Nanobiotix Alternatives ProQR Therapeutics Alternatives Acelyrin Alternatives Semper Paratus Acquisition Alternatives Monopar Therapeutics Alternatives China SXT Pharmaceuticals Alternatives SELLAS Life Sciences Group Alternatives Editas Medicine Alternatives Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:UNCY) was last updated on 7/16/2025 by MarketBeat.com Staff From Our PartnersMarket Panic: Trump Just Dropped a Bomb on Your Stockstock Market Panic: Trump Just Dropped a Bomb on Your Stocks The market is in freefall—and Trump's new tarif...American Alternative | SponsoredBanks aren’t ready for this altcoin—are you?Our expert analysts have identified a $100 billion gap in the crypto market. Only one project is perfectly ...Crypto 101 Media | SponsoredRevolutionary AI Tech Targets Early Diabetic Blindness Detection FDA Trial UnderwayTiny Stock, Massive Potential— this company’s AI platform is a game changer for healthcare!Interactive Offers | SponsoredINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | SponsoredThe Robotics Revolution has arrived … and one $7 stock could take off as a result.Something big is brewing in Washington. According to my research, an executive order from President Trump c...Weiss Ratings | SponsoredI warned you about Nvidia… now look what’s happeningNvidia just got Trump’s greenlight to sell high-powered AI chips to China — and their stock surged 5% before t...Timothy Sykes | SponsoredThis Social Security Shift Could Boost Benefits by 400%If you currently collect Social Security—or plan to in the future—this may be one of the most important update...InvestorPlace | SponsoredWhich Gold Miner Trades at 30% of NAV? The One Buffett WantsSome of the world’s best gold developers are trading at just 30% of NAV — like buying a dollar for 30 cents. ...Golden Portfolio | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Unicycive Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Unicycive Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
